Invitae puts forth $1.4B worth acquisition deal for ArcherDX
Category: #headlines  By Pranali Mehta  Date: 2020-06-24
  • share
  • Twitter
  • Facebook
  • LinkedIn
Invitae puts forth $1.4B worth acquisition deal for ArcherDX

Genetic testing company Invitae is reportedly on its way to purchasing personalized cancer test developer ArcherDX. The deal is speculated to have been finalized at USD 1.4 billion.

As per sources familiar with the knowledge of the matter, ArcherDX, earlier this month, had announced that it had been filing for a Nasdaq IPO worth USD 100 million. However, it seems to have canceled the IPO and gone ahead to be acquired by Invitae. The deal valuation is apparently inclusive of the shares of Invitae, upfront cash, and future milestone payments. Both the companies are planning to integrate their tumor profiling, liquid biopsy, and genomics technologies through a single overarching service.

The transaction will apparently commence with USD 325 million in cash along with 30 million shares of Invitae common stock, as well as an additional 27 million shares linked to milestones. The boards of both the companies have given their approval for the deal and it is expected to gain closure in the next several months.

It has been speculated that Invitae, in order to carry out the takeover, has set up a strategic financing equipped with more than USD 400 million in commitments from investors, with Perceptive Advisors in the lead. Invitae will sell USD 275 million of the stock through a private placement, at a rate of USD 16.85 per share, aided by Deerfield Management, Farallon, Redmile Group, Driehaus Capital Management, Casdin Capital, Soleus Capital, Rock Springs Capital, and PBM Capital.

Sean George, Co-founder and CEO, Invitae, has been quoted to state that the company aims to aggregate all genetic tests worldwide into a single platform and bring comprehensive genetic information into mainstream medicine, and this acquisition is a major step in that direction.

Jason Myers, Co-founder and CEO, ArcherDX, has been quoted to state that the firm is thrilled to acquire Invitae and form a nerve center for therapy optimization, precision oncology, monitoring, and diagnostics, and gain the opportunity for accelerating shareholder value and patient care.

Source Credits: https://www.fiercebiotech.com/medtech/archerdx-drops-ipo-plans-favor-a-1-4b-takeover-by-invitae

  • share
  • Twitter
  • Facebook
  • LinkedIn

About Author

Pranali Mehta

Pranali Mehta    

Pranali Mehta boasts of over three years of experience as a content writer. Having completed her graduation in chemical engineering, she worked as safety & environment associate in a chemical company for a year. Harnessing her passion for writing however, Pranali deci...

Read More >>

More News By Pranali Mehta

Air New Zealand exploring low-carbon tech to reduce fleet emission
Air New Zealand exploring low-carbon tech to reduce fleet emission
By Pranali Mehta

Air New Zealand Ltd. recently stated that it is learning to utilize low-carbon technologies such as hybrid, electric, or hydrogen-powered aircraft to drastically cut emissions from shorter and regional flights by 2030. Aviation accounts for about 2....

Siemens Gamesa raises capacity of 5.X wind turbine platform to 6.6MW
Siemens Gamesa raises capacity of 5.X wind turbine platform to 6.6MW
By Pranali Mehta

Renewable energy major, Siemens Gamesa has successfully increased the capacity of its next-generation onshore wind turbine platform, the Siemens Gamesa 5.X. With this upgrade, output of the platform’s SG 6.6-155 and SG 6.6-170 turbines has bee...

Amazon launches its largest fulfillment center in Bengaluru, India
Amazon launches its largest fulfillment center in Bengaluru, India
By Pranali Mehta

E-commerce major Amazon India has unveiled the largest fulfillment center in Bengaluru, which reportedly comes with a capacity of over 2.4 million cubic feet. The company mentioned in its official statement this new infrastructural expansion will pr...